XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues:        
Total revenues $ 6,260 $ 6,217 $ 12,850 $ 12,640
Costs and expenses:        
Cost of goods sold 1,442 1,390 2,866 2,751
Research and development expenses 1,102 1,092 2,280 2,142
Acquired in-process research and development expenses 330 138 338 205
In-process research and development impairment 0 0 2,700 0
Selling, general and administrative expenses 1,357 1,351 2,440 2,406
Total costs and expenses 4,231 3,971 10,624 7,504
Income from operations 2,029 2,246 2,226 5,136
Interest expense (242) (256) (480) (513)
Other income (expense), net (284) (173) (395) (542)
Income before income taxes 1,503 1,817 1,351 4,081
Income tax expense (368) (300) (204) (842)
Net income 1,135 1,517 1,147 3,239
Net loss attributable to noncontrolling interest 9 5 16 12
Net income attributable to Gilead $ 1,144 $ 1,522 $ 1,163 $ 3,251
Net income per share attributable to Gilead common stockholders - basic (in dollars per share) $ 0.91 $ 1.21 $ 0.93 $ 2.59
Shares used in per share calculation - basic (in shares) 1,256 1,255 1,255 1,256
Net income per share attributable to Gilead common stockholders - diluted (in dollars per share) $ 0.91 $ 1.21 $ 0.92 $ 2.58
Shares used in per share calculation - diluted (in shares) 1,260 1,260 1,261 1,261
Product sales        
Revenues:        
Total revenues $ 6,138 $ 6,152 $ 12,672 $ 12,492
Royalty, contract and other revenues        
Revenues:        
Total revenues $ 122 $ 65 $ 178 $ 148